Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc (GRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,324
  • Shares Outstanding, K 54,392
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,080 K
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GRTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.58
  • Most Recent Earnings $-0.07 on 08/14/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 194.47%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0610 +30.33%
on 08/20/24
0.0849 -6.36%
on 09/18/24
+0.0035 (+4.61%)
since 08/19/24
3-Month
0.0514 +54.67%
on 08/08/24
0.1475 -46.10%
on 07/08/24
-0.0037 (-4.45%)
since 06/18/24
52-Week
0.0514 +54.67%
on 08/08/24
0.2900 -72.59%
on 02/28/24
-0.1256 (-61.24%)
since 09/19/23

Most Recent Stories

More News
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American...

GRTX : 0.0795 (unch)
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...

GRTX : 0.0795 (unch)
Galera to Present at Jefferies Healthcare Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 0.0795 (unch)
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...

GRTX : 0.0795 (unch)
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...

GRTX : 0.0795 (unch)
Galera Announces Plan to Submit Avasopasem NDA by Year End

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...

GRTX : 0.0795 (unch)
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 0.0795 (unch)
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA...

GRTX : 0.0795 (unch)
Galera to Present at H.C. Wainwright BioConnect Conference

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 0.0795 (unch)
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026

Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...

ONCY : 0.9600 (+3.23%)
ONC.TO : 1.28 (unch)
ITCI : 75.18 (+0.64%)
LCTX : 0.9050 (+2.84%)
GILD : 84.11 (+0.26%)
GRTX : 0.0795 (unch)

Business Summary

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which...

See More

Key Turning Points

3rd Resistance Point 0.0996
2nd Resistance Point 0.0922
1st Resistance Point 0.0859
Last Price 0.0795
1st Support Level 0.0722
2nd Support Level 0.0648
3rd Support Level 0.0585

See More

52-Week High 0.2900
Fibonacci 61.8% 0.1989
Fibonacci 50% 0.1707
Fibonacci 38.2% 0.1425
Last Price 0.0795
52-Week Low 0.0514

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar